Zoetis Inc. · ZTS · FY2024 Q4 · Calendar Q1 2025

Zoetis: Durable Franchise Growth, but Competition Is Rising

The call provides evidence for a constructive one-year growth case: management highlighted expansion in parasiticides, osteoarthritis-pain biologics, alternative channels and the product pipeline. That case remains conditional because competition, pricing and volume mix, foreign exchange, regulatory scrutiny and the durability of margin improvement could offset franchise momentum.

Reported Before market openNYSEHealthcare $33.48B market cap
80quality score

Earnings scorecard

Reported versus consensus
Reported EPS — Consensus $1.37
EPS surprise — Reported versus consensus
Reported revenue — Consensus $2.32B
Revenue surprise — Reported versus consensus

Market reaction

prior-close to event-session close
Stock move -5.1% Event window
SPY move +1.1% Same window
Abnormal move -6.2% Stock minus SPY
Volume 4.7× Versus trailing sessions
Subsequent drift -2.2% Up to 20 sessions
ZTSSPY benchmark

Ask FN2 about ZTS FY2024 Q4

Transcript, numbers and history already loaded
What drove ZTS's -5.1% move after FY2024 Q4 earnings?What changed in ZTS's guidance and outlook in FY2024 Q4?Give me the bull and bear case for ZTS after FY2024 Q4 earnings.

Free account. Your question opens in FN2 with this report's transcript and numbers attached.

Transcript intelligence

What changed

Compared with the prior analysis, the outlook shifted from a raised FY2024 revenue view to a maintained 2025 framework. Management emphasized 2025 organic growth, continued expansion of Simparica, Librela and Solensia, and portfolio focus after the MFA divestiture.

Guidance delta

Management maintained its 2025 outlook, targeting 6–8% organic revenue growth and 2–4% adjusted net-income growth.

Key takeaways

  • Management described 11% operational revenue growth in FY2024, led by companion-animal franchises.
  • Simparica Trio, Librela and Solensia were identified as major growth drivers, alongside pipeline opportunities.
  • The 2025 outlook calls for 6–8% organic revenue growth and 2–4% adjusted net-income growth.
  • The investment case is supported by franchise expansion, but faces competition, pricing, foreign-exchange and regulatory risks.

Management priorities

  • Expand Simparica, Librela, Solensia and other key franchises through omni-channel distribution.
  • Advance pipeline products and long-acting formulations in chronic kidney disease, oncology and cardiology.
  • Use field-force education and veterinary outreach to support adoption and market share.
  • Focus the portfolio on higher-growth, higher-value lines following the MFA divestiture.

Follow ZTS with an agent that reads every filing, transcript, and price print. Free to start.

Try FN2 free

Earnings History

Estimate Beat Miss Match
ZTS EPS earnings history estimate and actual scatter chart 9 reported fiscal quarters and 3 future estimate-only quarters. Q4 '23 estimate $1.32 Q4 '23 actual $1.24, miss Q1 '24 estimate $1.34 Q1 '24 actual $1.38, beat Q2 '24 estimate $1.49 Q2 '24 actual $1.56, beat Q3 '24 estimate $1.46 Q3 '24 actual $1.58, beat Q2 '25 estimate $1.62 Q2 '25 actual $1.76, beat Q3 '25 estimate $1.62 Q3 '25 actual $1.70, beat Q4 '25 estimate $1.40 Q4 '25 actual $1.48, beat Q1 '26 estimate $1.60 Q1 '26 actual $1.53, miss Q2 '26 estimate $1.85 Q2 '26 actual $1.87, beat Q3 '26 estimate $1.51 Q4 '26 estimate $1.63 Q1 '27 estimate $1.62
Show less

Analyst Consensus ?

ConsensusHold32 ratings
Bullish1443.8%
Neutral1856.2%
Bearish00.0%

Analyst 52W Price Targets

$81.03Current
$74Low
$135.12Average
$254High

Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Oct 24, 2026. Not an FN2 forecast.

Firm-level rating actions

FMP grade actions identify the grading firm, not a named analyst.

FirmRatingPrior ratingActionDate
Jefferies Hold BuyDowngradeOct 20, 2026
TD Cowen Buy BuyMaintainAug 25, 2026
Stifel Hold HoldMaintainAug 20, 2026
Citigroup Buy BuyMaintainAug 11, 2026
BNP Paribas Outperform OutperformMaintainAug 11, 2026
Show 27 more rating actions

Named analyst price targets

Upside is calculated against the persisted current price $81.03. FMP does not supply a rating on these named-analyst rows.

FirmAnalyst52W targetPrice when postedUpsideDate
JefferiesKeith Devas$83$79.59 +2.4%Oct 20, 2026
Goldman SachsAnalyst unavailable$74$78.42 -8.7%Oct 16, 2026
Cantor FitzgeraldAnalyst unavailable$94$77.17 +16.0%Aug 25, 2026
Stifel NicolausJonathan Block$80$76.68 -1.3%Aug 20, 2026
Morgan StanleyAnalyst unavailable$85$75.3 +4.9%Aug 7, 2026
See 31 more

Track every rating change on ZTS the moment it posts. Free to start.

Start free

Company context

Snapshot as of publication

Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology.…

Historical context

All ZTS earnings
+3.9%FY2026 Q2 · Calendar Q3 2026-21.5%FY2026 Q1 · Calendar Q2 2026-2.4%FY2025 Q4 · Calendar Q1 2026

Healthcare peers this season

Latest reports in the same sector
CompanyQuarterEPS surpriseMarket moveHeadline
RDY Dr. Reddy's Laboratories Limited FY2027 Q2 · Calendar Q4 2026 +24.0% -0.2% Dr. Reddy’s: margins improve as semaglutide rollout advances
DGX Quest Diagnostics Incorporated FY2026 Q3 · Calendar Q4 2026 +4.5% +1.8% Quest Diagnostics: growth broadens, but PAMA remains a headwind
ARGX argenx SE FY2026 Q3 · Calendar Q4 2026 — -1.6% argenx: VYVGART momentum and a broader late-stage pipeline
MEDP Medpace Holdings, Inc. FY2026 Q3 · Calendar Q4 2026 +9.0% -1.3% Medpace: Record awards lift backlog as 2026 outlook improves
MOH Molina Healthcare, Inc. FY2026 Q3 · Calendar Q4 2026 +12.7% +0.8% Molina reaffirms 2026 outlook as Florida contract scales

Latest beats and misses

Who reports next

Beat on EPS

Missed on EPS

Get the ZTS recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Sources

  1. Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
  2. FN2 earnings calendar · 2025-01-30T00:03:07.291072+00:00
  3. Polygon adjusted daily market bars · 2026-10-24T17:20:42.828996+00:00
  4. Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-24T17:20:42.826135+00:00

Methodology

Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.

Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.

Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.

By FN2 Research · Updated · As of 2026-10-24. For educational purposes only; not investment advice.